Tall Allen said...
You certainly can have salvage radiation to the entire lymph node field. One HW member, Bob, had exactly that done. His doctor (Dattoli) used many very small doses to achieve a much higher total dose. Unfortunately in his case, it had already spread to bone. I don't know if that is better than conventional IMRT fractionation (1.8 Gy) to a total dose of 50-55 Gy, or SBRT to a total dose of 25 Gy in 5 fractions. All seem to have low acute toxicity.
To be more precise, my RO didn't say he couldn't radiate the lymph node field, he said he didn't think he could deliver enough radiation to the entire field to make much of a difference, while keeping toxicities low. Keep in mind that at the time I had no evidence of lymph node involvement. Had there been such evidence, he may have upped the toxicity risk. Although, looking back, I wish he had been more aggressive, I think he and I made the right call with the info we had at the time. And this guy was no slouch, he was the head of radiation oncology at one of the most recognizable national hospitals.
Tall Allen said...
So it behooves the patient to treat the entire (extended) area. Here's an article suggesting that it is an effective approach wen any cancerous LNs have been detected...
Interesting. But I also note that the article says "None of these studies reported the toxicity of the salvage treatment, but with improved external beam radiation techniques and scrupulous image guidance, toxicity has been improving." I am not sure what "has been improving means," but I suspect that with the technology available five years ago when I had SRT the concern about
toxicity of wide field radiation was more significant than it might be today. At least at all but the most dedicated centers.
Tall Allen said...
As for "whack-a-mole," there is no evidence that it makes a significant difference. There has been only one pilot trial ever that had a control group, which you can read about here:
/pcnrv.blogspot.com/2017/12/metastasis-directed-therapy-for.html
Why would you risk playing whack-a-mole when there is no evidence of benefit, and it might preclude further treatment?
Fair question. I don't understand why it would preclude further treatment, since the only further treatment I can think of is ADT, and that is not precluded, just delayed. But as far as benefit, yes, no benefit at the 80% confidence level, but maybe I am willing to roll the dice betting that there really is a benefit ("Median ADT-free survival was 8 months longer in the MDT group") it's just that the N was not high enough for statistical significance.
But your point is well taken. I note from the paper that "We recently saw that there is a clinical trial at Johns Hopkins to detect and treat oligometastases using the more accurate PSMA PET scan. While outcomes may be improved with a more accurate scan, it will undoubtedly eliminate many patients from the oligometastatic pool of patients."
I applied for that trial but was told that I am too early. But I may re apply if I reach psa of 1.0
Tall Allen said...
I never heard of anemia from PLN treatment -- a good RO will scrupulously limit dose to bones.
That's good to know. That was a comment from my urologist, who is not a RO.